BenevolentAI
Facts
as of Nov 22, 2026BenevolentAI is a British company founded in London in 2013 that applies machine learning to drug discovery, building a knowledge graph from scientific literature, clinical data and experimental results to propose new targets and treatments. Its best known result came in 2020, when the platform identified the arthritis drug baricitinib as a potential COVID-19 therapy, a hypothesis later confirmed in trials and approved by regulators. The company listed on Euronext Amsterdam in 2022, delisted in 2024 after restructuring and heavy cost reductions, and now runs a narrower pipeline alongside partnerships with pharmaceutical companies including AstraZeneca and Merck.
- Legal name
- BENEVOLENTAI LIMITEDactive
- Headquarters
- London, United Kingdom
- Founded
- 2013
- Employees
- 51-200estimated range
- Register numbers
- CRN 09781806
- Website
- benevolent.com
These are the key facts about BenevolentAI on Alion as of Nov 22, 2026. BenevolentAI is headquartered in London, United Kingdom. It was founded in 2013.
Funding
Full ledger, 7 records →BenevolentAI: 7 money records, each linked to its source.
Products
Products →BenevolentAI names 4 products on its own site.
Risk
Full record →BenevolentAI: 62 research papers in five years.
Footprint
Hiring in 1 city in 1 country.
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| London United Kingdom | Headquarters | 0 |
